Acasti Pharma, a subsidiary of Neptune Technologies & Bioresources, Inc., is engaged in the development of a portfolio of proprietary novel long-chain omega-3 phospholipids, which are the main component of cell membranes and are essential to all vital cell processes. The company is initially focusing on treatments for chronic cardiovascular and cardiometabolic conditions within the over-the-counter, medical food and prescription drug markets. For more information, visit the company’s Web site: http://www.acastipharma.com

Let us hear your thoughts below: